- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00079495
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis
We are studying this investigational drug treatment, comparing it with placebo, to evaluate whether it is effective in reducing the number of MRI lesions with a minimum number of side effects. The investigational drug will be administered in the clinic weekly for 5 injections (induction phase) then monthly for 8 additional injections (maintenance phase).
Approximately 150 male and female patients (100 active and 50 placebo), aged 18 to 55 years, with relapsing MS and at least one but no more than 10 total Gd-enhancing lesions on cranial MRI scans during the run-in phase will be randomized into this study.
Descripción general del estudio
Descripción detallada
Tipo de estudio
Inscripción
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female, 18 to 55 years of age
- Diagnosed with relapsing multiple sclerosis, with at least one relapse in the last two years
- Females must not plan on becoming pregnant
- Females must either be post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control and willing to continue birth control until 30 days after the last dose of study drug
- Males must not intend to impregnate a partner during the study or for 30 days after the study and must also practice acceptable birth control with their partners
Exclusion Criteria:
- Significant long-lasting disease of the immune system other than multiple sclerosis
- Past or current medical disease (heart, liver, kidney, etc.) including severe asthma, cancer or advancing brain or spinal cord disorder
- Known or suspected long-lasting infectious disease including HIV, hepatitis B, or hepatitis C
- Treatment with certain steroid or hormone medications within 30 days before the pre-study MRI scan
- Treatment with other medications that suppress the immune system within 6 months before the pre-study MRI scan
- Certain treatments and medications are not allowed
- Laboratory and other tests will be performed to determine further eligibility
- History of drug or alcohol abuse in the last year
- History of medical or psychiatric condition that could pose a risk for participation in the study
- Females who are pregnant or breast feeding
- Participation in any other trial of an investigational agent within 90 days before the start of the study
- History of not following instructions with past therapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NBI-5788-0201
- MS APL
- Neurocrine
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre NBI-5788
-
Ono Pharmaceutical Co. LtdTerminado
-
Ono Pharmaceutical Co. LtdTerminado
-
Portuguese Oncology Institute, CoimbraTerminadoCáncer colonrectal | Recurrencia, Neoplasia LocalPortugal
-
Prince of Songkla UniversityTerminadoNeoplasias colorrectales | Pólipo colorrectalTailandia
-
Midwest Biomedical Research FoundationMedical University of South Carolina; Academisch Medisch Centrum - Universiteit... y otros colaboradoresTerminadoReflujo gastroesofágico | Esófago de BarrettEstados Unidos, Países Bajos
-
Shanghai Jiao Tong University School of MedicineTerminadoCáncer gástrico tempranoPorcelana
-
Shanghai Jiao Tong University School of MedicineBeijing Friendship Hospital; The Third Xiangya Hospital of Central South University y otros colaboradoresReclutamientoPólipos colorrectales diminutosPorcelana
-
The Leeds Teaching Hospitals NHS TrustDesconocidoColitis ulcerosa (CU)Reino Unido
-
Lotung Poh-Ai HospitalTerminado
-
Changhai HospitalThe Second Hospital of Hebei Medical University; Air Force Military Medical University... y otros colaboradoresReclutamientoLesión serrada sésil colorrectalPorcelana